
This system enables researchers to study cell interactions. The prototype consists of two integrated modules: the optical tweezers and the digital holographic microscope.
To improve medical treatment, researchers test new drug ingredients on biological cells. By combining two microscopy techniques, the time required for testing can be reduced by 50 to 80 percent.
And far fewer measurements are needed.
When developing new medications, biologists and pharma- cologists test different active ingredients and chemical compounds. The main purpose is to find out how biological cells react to these substances. To do so, researchers often use a fluorescence microscope that produces digital, holo- graphic images, i.e. computer-generated holograms in which the cells being studied can be viewed in three dimen- sions. The hologram is first created as an optical image, which is then digitized for recording and analysis on the computer. The computer calculates the data needed to display the three-dimensional image of the cells. This method has several advantages. The researchers don’t have to use markers to make the cells visible. They can examine the cells without touching them. And the cells can be characterized in vivo – scientists refer to this as in vivo testing.
To obtain precise and reliable answers to the question of how the cells react to chemical substances, each cell must be placed in an individual, tiny hollow (well) on a microfluidic chip, i.e. one cell per well. This ensures that the cells are not influenced by the presence of other cells. Another requirement is that the cells must be of the same size, so that their reactions to the active agent can be compared. The problem is that it is difficult to transfer single cells to the tiny wells. Often, the researchers pour them in together with the nutrient solution in which they were grown. This can have two unwanted consequences: firstly that several cells occupy the same well and secondly that the cells are of all different sizes. It can even happen that cells swim out of the wells during the test. The researchers have to take all these factors into account by employing statistical averaging. In other words they have to carry out innumerable measurements and test large numbers of cells in order to obtain a scientifically accurate result – an undertaking that can be extremely tedious and time-consuming.
Combination of digital holographic microscopy and optical tweezers
Researchers at the Fraunhofer Institute for Production Technology IPT in Aachen have found a solution to this problem. “It combines digital holographic microscopy with the use of optical tweezers,” reveals IPT group manager Stephan Stürwald. Optical tweezers are a special instrument that uses the force of a focused laser beam to trap and move micro- scopic objects. This tool enables the researchers to pick up selected cells, transfer them to individual wells of a microarray, and keep them trapped there. “By combining these two instruments, we can save between 50 and 80 percent of the time normally needed for such work, depending on the type of cell and the test method employed. That’s mainly because we don’t have to carry out so many repeated measurements,” explains Stürwald. The system is very easy to use, and the optical tweezers can also be controlled via the touchscreen of a tablet PC.
The combination of these two techniques not only simplifies current test procedures but also allows new tests to be developed. For instance, it is possible to position cells at a defined distance from one another, thus creating different patterns. In this way, the scien- tists will be able to observe cell interactions, because the spacing between them is ident- ical and fixed. One possible application is in the study of apoptosis, or sudden cell death. When a cell dies by apoptosis, it excretes substances that affect the behavior of other cells around it. But within what radius? Researchers will now be able to directly answer this question. The new system will also enable them to use the laser to selectively destroy cells that that are unsuitable for testing. A prototype of the system has already been built. It con- sists of two modules: the optical tweezers and the digital holographic microscope. The researchers have successfully carried out initial tests using the new system.
The Latest on: Testing of new pharmaceuticals
[google_news title=”” keyword=”Testing of new pharmaceuticals” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Testing of new pharmaceuticals
- AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Updateon March 30, 2023 at 3:05 pm
Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023AcelRx advancing its proprietary Niyad™ nafamastat ...
- Pharmaceutical Analytical Testing Outsourcing Market 2023 [New Report] | Industry Size Expected Growth Rate up to 2030 | 122 Pages Reporton March 29, 2023 at 2:37 am
The Pharmaceutical Analytical Testing Outsourcing Market (2023-2030) latest Research Report predicts significant growth ...
- Pharmaceutical Analytical Testing Outsourcing Market 2023 Size and Forecast to 2031on March 28, 2023 at 6:31 pm
Pharmaceutical Analytical Testing Outsourcing Marketinformation for each competitor includes (Toxikon, Eurofins ...
- LMHRA Promises Continual Regulatory Support to Global Pharmaceuticalson March 28, 2023 at 4:10 am
The Managing Director of the Liberia Medicines and Health Products Regulatory Authority, Pharmacist Keturah C. Smith-Chineh, has vowed the authority's continual support to the growth of the Global ...
- Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researcherson March 17, 2023 at 9:37 am
via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of ...
- Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researcherson March 15, 2023 at 6:11 am
WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, ...
- Pharmaceutical Analytical Testing Outsourcing Market And Its Economic Impact On Industry Upto 2028on March 9, 2023 at 1:18 am
(MENAFN- The Express Wire) Global Pharmaceutical Analytical Testing Outsourcing Market 2023 New Updated Research Report is spread across 107 pages and provides Size, Share, Growth, and Forecast ...
- The Future Of Pharmaceutical Quality Control Testing Market: Opportunities And Challenges 2022-2028on February 27, 2023 at 6:31 am
Pharmaceutical Quality Control Testing Market Size is projected to Reach ... mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these ...
- Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatmenton July 2, 2021 at 7:31 am
“The company has instructed investigators to pause new screening, enrollment, and any further dosing of investigational ARO-ENaC pending additional data from the ongoing chronic rat toxicology ...
- Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticalson May 14, 2021 at 3:56 am
New models of outsourcing clinical research restructured how pharmaceutical companies test their investigational drugs from Phase I through Phase IV trials. Beginning in the 1980s, for-profit ...
via Bing News